Objective. MMP is a key enzyme in the degradation of extracellular matrices, and its expression plays important roles in inflammatory diseases. Cordycepin (3 0 -deoxyadenosine), a bioactive compound of Cordyceps militaris, has been shown to exhibit many pharmacological activities, such as anti-cancer, anti-inflammatory and anti-infection activities. In this study, we aimed at the inhibitory effect of cordycepin on IL-1b-induced MMP-1 and MMP-3 expression as well as the molecular basis using RA synovial fibroblasts (RASFs). Methods. RASFs were isolated from synovial tissue obtained from 12 patients with RA and cultured in monolayer. Expression of MMP-1 and MMP-3 was evaluated using western blotting and real-time PCR. Chemokines were analysed by ELISA. The phosphorylation of mitogenactivated protein kinase was measured by western blotting. Electrophoretic mobility shift assay was performed to evaluate binding activities of DNA to nuclear factor-kB (NF-kB) and activator protein-1 (AP-1).
Introduction
Cordyceps militaris, a species of the fungal genus Cordyceps, is an ingredient of traditional Chinese medicine and has been prescribed for inflammatory diseases and cancer [1, 2] . Extract of Cordyceps exhibits anti-tumour effects on cancers and inhibitory effects on the production of inflammatory mediators [3, 4] . Cordycepin, which is a nucleoside derivative isolated from Cordyceps, has been reported to exert inhibitory effects on macrophages based on anti-inflammatory property [5] .
RA is a chronic inflammatory disease that causes progressive joint destruction. It is characterized by synovial hyperplasia and joint destruction [6, 7] . The cartilage destruction observed in RA is mostly caused by the activation of MMPs [8] . MMP-1 and -3 have been shown to be the major enzymes produced by fibroblasts in the synovium [9] . MMP-1 preferentially degrades fibrillar collagens, whereas MMP-3 degrades a broad array of extracellular matrix substrates [10] [11] [12] . Pro-inflammatory cytokines such as IL-1b and TNF-play critical roles in the pathogenesis of RA [13] . It is well known that cytokines stimulate production of MMPs through the activation of cellular signalling pathways involving mitogen-activated protein kinases (MAPKs), nuclear factor-kB (NF-kB) and activator protein-1 (AP-1) [14] [15] [16] . In response to cytokines, RA synovial fibroblasts (RASFs) produce chemokines, including b-chemokine regulated on activation normal T-cell expressed and secreted (RANTES/CCL5), epithelial neutrophil-activating peptide-78 (ENA-78/CXCL5), monocyte chemoattractant protein-1 (MCP-1/CCL2) and growth-regulated oncogene-(GRO-/CXCL1), which further promote inflammation and cartilage destruction by inducing MMP activity and expression [5, 17, 18] .
In this study, we investigated the inhibitory effect of cordycepin on IL-1b-induced MMP-1 and -3 expression as well as the molecular basis in RA inflammation using RASFs.
Materials and methods

Materials
Cordycepin was purchased from Sigma (St Louis, MO, USA). IL-1b, TNF-and antibodies for MMP-1 and -3 were from R&D Systems (Minneapolis, MN, USA). High glucose-containing DMEM and fetal bovine serum (FBS) were obtained from Gibco-BRL (Gaithersburg, MD, USA). Antibodies for p38, p-p38, JNK, p-JNK, extracellular signal-regulated kinase (ERK) and p-ERK were purchased from Cell Signaling Technology (Beverly, MA, USA).
Determination of cell viability
RASFs (2 Â l0 4 cells/well) were treated with various concentrations of cordycepin. After incubation for 1 h, 12 h and 24 h, cells were washed twice with PBS, MTT (0.5 mg/ml PBS) was added to each well and incubated at 378C for 30 min. Formazan crystals formed were dissolved by adding DMSO (100 ml/well) and the absorbance was read at 570 nm using a microplate reader (Model 3550, Bio-Rad, Richmond, CA, USA).
Western blot analysis
RASFs (5 Â 10 6 cells) were pre-treated with cordycepin for 1 h and then incubated with IL-1b (5 ng/ml) or TNF-(5 ng/ml) for 24 h. Cells were lysed with 40 ml of ice-cold lysis buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 0.1% SDS). Samples were separated by SDS-PAGE with 10% polyacrylamide gels and electrotransferred into polyvinylidene fluoride (PVDF). The PVDF membranes were blotted with 1 mg/ml of primary antibodies for p38, p-p38, JNK, p-JNK, ERK, p-ERK, b-actin, MMP-1 and MMP-3. HRP-conjugated IgG was used as a secondary antibody. The protein expression levels were then determined by analysing the signals captured on the PVDF membranes using an image analyser (Las-1000, Fujifilm, Tokyo, Japan).
Quantitative real-time PCR assay
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized from 1 mg total RNA using oligo-dT primers and AMV reverse transcriptase (Takara, Shiga, Japan). The expression of MMP-1 and -3 mRNA was determined by real-time RT-PCR using the ABI Prism 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA) and SYBR Premix Ex Taq (Takara). The primers were: MMP-1 (NM 002424.2) sense, AGTGA CTGGGAAACCAGATGCTGA; anti-sense, GCTCTTGGCAA ATCTGGCCTGTAA and MMP-3 (NM 002422) sense, ATTCC ATGGAGCCAGGCTTTC; anti-sense, CATTTGGGTCAAAC TCCACTGTG and GAPDH (NM 002046) sense, ATGGAA ATCCCATCACCATCTT; anti-sense, CGCCCCACTTGATTT TGG. To control variation in mRNA concentration, all results were normalized to the housekeeping gene, GAPDH. Relative quantitation was performed using comparative ÁÁC t method according to the manufacturer's instructions.
ELISA of chemokines
RASFs were pre-treated with cordycepin (50 mM and 100 mM) for 1 h and then incubated with IL-1b (5 ng/ml). After 24 h, culture medium was collected and centrifuged at 10 000 g for 5 min at 48C to remove particulates. Quantities of RANTES, ENA-78, MCP-1 and GRO-were determined using Quantikine ELISA kits (R&D Systems). Optical density was determined with Microplate reader (Model 3550, Bio-Rad). A standard curve of each cytokine was established using known concentrations of cytokine by plotting optical density vs log of the concentration.
Electrophoretic mobility shift assay
RASFs (5 Â 10 6 cells) were treated with IL-1b (5 ng/ml) in the presence of cordycepin for 1 h. Cells were then washed with cold PBS. The activation of NF-kB and AP-1 was assayed by a gel mobility shift assay using nuclear extracts [21] . An oligonucleotide containing k-chain binding site (kB, 5 0 -CCGGTTAACAGAGG GGGCTTTCCGAG-3 0 ) and AP-1 (5 0 -CGCTTGATGAGTCA GCCGGAA-3 0 ) was synthesized and used as a probe. The two complementary strands were then annealed and labelled with [-32 P]dCTP. Labelled oligonucleotides (10 000 cpm), 10 mg of nuclear extracts, and binding buffer [10 mM Tris-HCl, pH 7.6, 500 mM KCl, 10 mM EDTA, 50% glycerol, 100 ng poly (dIÁdC), 1 mM dithiothreitol] were then incubated for 30 min at room temperature in a final volume of 20 ml. The reaction mixtures were analysed by electrophoresis on 4% polyacrylamide gels in 0.5 Â Tris-borate buffer, and the gels were then dried and examined by autoradiography. Specific binding was controlled by competition with a 50-fold excess of cold kB or cold AP-1 oligonucleotide.
Statistical analysis
Statistical analysis of the data was performed using ANOVA and Duncan's test. Differences with P < 0.05 were considered statistically significant.
Results
Effect of cordycepin on cell viability of RASFs
Cytotoxicity of cordycepin on RASFs has not yet been reported. Therefore, the effect of cordycepin on cellular toxicity of RASFs was assessed using MTT assay. Treatment of RASFs with cordycepin (50 mM or 100 mM) for 24 h did not cause any significant change in cell viability. However, cell viability was slightly decreased when cells were incubated with 100 mM cordycepin for 48 h (data not shown).
Effect of cordycepin on IL-1-induced MMP-1 and -3 expression in RASFs
We performed western blot analysis and real-time PCR to investigate the effect of cordycepin on IL-1b or TNF--induced MMP-1 and -3 expressions. Western blot analysis revealed that treatment of RASFs with IL-1b or TNF-increased the levels of MMP-1 and -3 (Fig. 1A) . Pre-treatment with cordycepin for 1 h completely blocked the up-regulation of MMP-1 and -3 induced by IL-1b but slightly by TNF- (Fig. 1A) . Real-time PCR revealed that IL-1b increased the level of MMP-1 and -3 in RASFs and cordycepin blocked IL-1b-induced up-regulation of MMP-1 and -3 in a dose-dependent manner (Fig. 1B) . Cordycepin itself had no effect on either MMP-1 or MMP-3 in RASFs (data not shown). These results indicate that cordycepin is a potent inhibitor of IL-1b-induced MMP-1 and -3 expression in RASFs.
Effect of cordycepin in IL-1-induced chemokine production
To determinate the action of cordycepin in regulating the production of IL-1b-induced chemokines, we measured chemokine levels. As shown in Fig. 1C , IL-1b increased significantly the levels of MCP-1, RANTES, GRO-and ENA-78 compared with vehicle. However, pre-treatment with cordycepin (100 mM) resulted in a significant inhibition of IL-1b-induced ENA-78 production, but not RANTES, MCP-1 and GRO-production, indicating that cordycepin specifically blocks ENA-78 induction in IL-1b signalling.
Effects of cordycepin on the MAPK signalling pathway by IL-1
The upstream regulatory regions of MMP genes contain the AP-1 recognition site. AP-1 can be activated by MAPK family [22, 23] . MAPK signalling pathway has been shown to be involved in IL-1b-induced MMP expression [24] . To investigate which MAPK is inhibited, the effect of cordycepin on IL-1b-induced activation of MAPK was elucidated by using western blotting. As shown in Fig. 2A , treatment with IL-1b significantly enhanced phosphorylation of p38, JNK and ERK. Pre-treatment with cordycepin blocked IL-1b-induced phosphorylation of p38 and JNK, but not ERK phosphorylation.
Effect of cordycepin on IL-1-induced NF-kB and AP-1 DNA binding activities
To clarify the mechanism of cordycepin-mediated inhibition of MMP-1 and -3 expression, the effect of cordycepin on IL-1b -induced activation of NF-kB and AP-1 was evaluated using electrophoretic mobility shift assay (EMSA). As shown in Fig. 2B , IL-1b increased substantially NF-kB and AP-1 binding activity. Pre-treatment with cordycepin inhibited IL-1b-stimulated AP-1 binding activity but not NF-kB binding activity. Cordycepin itself had no effect on NF-kB and AP-1 binding activities. These results suggest that cordycepin specifically blocks AP-1 activation in IL-1b signalling.
Discussion
In this study, we have for the first time provided evidence that cordycepin inhibits IL-1b-induced expression of MMP-1 and -3 and production of chemokines in cultured RASFs. Our results also showed that cordycepin blocked IL-1b-mediated activation of AP-1, but not NF-kB, and phosphorylation of p38 and JNK, but not other MAPK families.
MAPK pathway is involved in regulation of cell proliferation, apoptosis, cytokine expression and MMP production. Three major MAPK families, JNK, ERK and p38 kinase, are expressed and the active phosphorylated forms can be detected in synovial tissue and cultured RASFs [25, 26] . In the present study, our results suggest that cordycepin inhibits MAPK activation, specifically p38 and JNK activation, in IL-1b signalling. Supporting our observations, cordycepin inhibits the phosphorylation of p38 in macrophage cells [27] . Importantly, p38 plays a major role in the production of pro-inflammatory cytokines, including TNF and IL-1b [28] . Indeed, p38 inhibitors have been successfully tested in animal models of arthritis, such as CIA [28, 29] . A potent p38 inhibitor, SB 203580, blunts enhancement of secreted MMP-1 and -3 levels elicited by IL-1b [10] . These findings suggest that cordycepin inhibits IL-1b-induced MMP expression through inhibition of p38/JNK activation.
NF-kB and AP-1 have an important role in RA pathogenesis [30] . Cytokines induce the activation of AP-1 and NF-kB in RA [31, 32] . Cytokine-induced MMP expression is regulated by MAPK activation and transcriptional activation of AP-1 [33] [34] [35] . MMP induction by cytokines is different depending on type of MMPs and cells. In SW1353 chondrosarcoma cells and rabbit articular chondrocytes, IL-1b-dependent synthesis of MMP-13 requires p38, JNK and NF-kB, but MMP-1 induction depends on p38 and ERK but not JNK or NF-kB [36] . In SFs, AP-1 is an essential component for MMP-1 synthesis, and cooperation between MAPK and NF-kB signalling pathways is necessary for IL-1b-dependent synthesis of MMP-1 [37, 38] . Our results show that cordycepin inhibited MMP-1 and -3 production by suppression of AP-1, but not NF-kB in RASFs.
Production of chemokines, such as MCP-1, GRO-, RANTES and ENA-78 in synoviocytes has been shown to induce proliferation of the cells and to facilitate their invasion into the adjacent tissues [39] . Chemokines play a role in the breakdown of cartilage by inducing the release of MMPs [39] [40] [41] . In this study, we found that IL-1b increased production of several chemokines in RASF. ENA-78 plays a critical role in the recruitment of inflammatory leucocytes into the joints of RA patients [42] . Moreover, ENA-78 also plays an important role in progression and maintenance of RA [43] [44] [45] . Our results showed that production of ENA-78 was enhanced by IL-1b and cordycepin specifically suppressed the Level of MCP-1, GRO-, RANTES and ENA-78 in culture media was measured using a Quantikine ELISA kit (C). Each value represents the mean AE the SEM of three independent experiments. *P < 0.01 vs untreated control; # P < 0.01 vs IL-1b.
production of ENA-78 in a dose-dependent manner, indicating that cordycepin is an inhibitor of ENA-78-mediated pathogenesis.
In conclusion, our results have demonstrated that cordycepin is a potent inhibitor of IL-1b-induced chemokine production and MMP expression and strongly blocks the ability of AP-1 and p38/JNK signalling pathway in RASF. Cordycepin in combination with pentostatin is under a Phase I clinical trial on chronic myelogenous leukaemia. In dogs, 8 mg/kg/day is the absolute limit for short-term treatment [46] . The dose of cordycepin that can inhibit IL-1b-induced chemokine production and MMP expressions is below the toxicity limit. Thus, cordycepin may be a potential candidate to prevent inflammation of RA.
